Clinical  ||| S:0 E:9 ||| JJ
roundtable  ||| S:9 E:20 ||| JJ
monograph ||| S:20 E:29 ||| NN
:  ||| S:29 E:31 ||| :
Recent  ||| S:31 E:38 ||| JJ
advances  ||| S:38 E:47 ||| NNS
in  ||| S:47 E:50 ||| IN
the  ||| S:50 E:54 ||| DT
treatment  ||| S:54 E:64 ||| NN
of  ||| S:64 E:67 ||| IN
mantle  ||| S:67 E:74 ||| JJ
cell  ||| S:74 E:79 ||| NN
lymphoma ||| S:79 E:87 ||| NNS
:  ||| S:87 E:89 ||| :
a  ||| S:89 E:91 ||| DT
post-ASH  ||| S:91 E:100 ||| JJ
2009  ||| S:100 E:105 ||| CD
discussion  ||| S:105 E:116 ||| NN
Mantle  ||| S:116 E:123 ||| NNP
cell  ||| S:123 E:128 ||| NN
lymphoma  ||| S:128 E:137 ||| NNS
( ||| S:137 E:138 ||| -LRB-
MCL ||| S:138 E:141 ||| NNP
)  ||| S:141 E:143 ||| -RRB-
is  ||| S:143 E:146 ||| VBZ
a  ||| S:146 E:148 ||| DT
rare  ||| S:148 E:153 ||| JJ
subtype  ||| S:153 E:161 ||| NN
of  ||| S:161 E:164 ||| IN
non-Hodgkin  ||| S:164 E:176 ||| JJ
lymphoma  ||| S:176 E:185 ||| NNS
characterized  ||| S:185 E:199 ||| VBN
by  ||| S:199 E:202 ||| IN
CD5  ||| S:202 E:206 ||| CD
expression  ||| S:206 E:217 ||| NN
and  ||| S:217 E:221 ||| CC
a  ||| S:221 E:223 ||| DT
t ||| S:223 E:224 ||| NN
( ||| S:224 E:225 ||| -LRB-
11 ||| S:225 E:227 ||| CD
; ||| S:227 E:228 ||| :
14 ||| S:228 E:230 ||| CD
)  ||| S:230 E:232 ||| -RRB-
cytogenetic  ||| S:232 E:244 ||| JJ
translocation  ||| S:244 E:258 ||| NN
that  ||| S:258 E:263 ||| IN
results  ||| S:263 E:271 ||| NNS
in  ||| S:271 E:274 ||| IN
overexpression  ||| S:274 E:289 ||| NN
of  ||| S:289 E:292 ||| IN
the  ||| S:292 E:296 ||| DT
cyclin  ||| S:296 E:303 ||| JJ
D1  ||| S:303 E:306 ||| CD
gene ||| S:306 E:310 ||| NN
.  ||| S:310 E:312 ||| .
Currently ||| S:312 E:321 ||| RB
,  ||| S:321 E:323 ||| ,
there  ||| S:323 E:329 ||| EX
is  ||| S:329 E:332 ||| VBZ
no  ||| S:332 E:335 ||| DT
standard  ||| S:335 E:344 ||| NN
of  ||| S:344 E:347 ||| IN
care  ||| S:347 E:352 ||| NN
for  ||| S:352 E:356 ||| IN
the  ||| S:356 E:360 ||| DT
treatment  ||| S:360 E:370 ||| NN
of  ||| S:370 E:373 ||| IN
MCL ||| S:373 E:376 ||| NNP
,  ||| S:376 E:378 ||| ,
and  ||| S:378 E:382 ||| CC
patient  ||| S:382 E:390 ||| JJ
prognosis  ||| S:390 E:400 ||| NN
is  ||| S:400 E:403 ||| VBZ
poor ||| S:403 E:407 ||| JJ
.  ||| S:407 E:409 ||| .
Traditional  ||| S:409 E:421 ||| JJ
treatments  ||| S:421 E:432 ||| NNS
for  ||| S:432 E:436 ||| IN
MCL  ||| S:436 E:440 ||| NNP
rely  ||| S:440 E:445 ||| VBP
on  ||| S:445 E:448 ||| IN
conventional  ||| S:448 E:461 ||| JJ
chemotherapy  ||| S:461 E:474 ||| JJ
agents ||| S:474 E:480 ||| NNS
,  ||| S:480 E:482 ||| ,
including  ||| S:482 E:492 ||| VBG
cyclophosphamide ||| S:492 E:508 ||| NN
,  ||| S:508 E:510 ||| ,
doxorubicin ||| S:510 E:521 ||| NN
,  ||| S:521 E:523 ||| ,
vincristine ||| S:523 E:534 ||| NN
,  ||| S:534 E:536 ||| ,
and  ||| S:536 E:540 ||| CC
prednisone  ||| S:540 E:551 ||| NNS
( ||| S:551 E:552 ||| -LRB-
CHOP ||| S:552 E:556 ||| NNP
) ||| S:556 E:557 ||| -RRB-
.  ||| S:557 E:559 ||| .
The  ||| S:559 E:563 ||| DT
addition  ||| S:563 E:572 ||| NN
of  ||| S:572 E:575 ||| IN
the  ||| S:575 E:579 ||| DT
immunotherapeutic  ||| S:579 E:597 ||| JJ
agent  ||| S:597 E:603 ||| NN
rituximab  ||| S:603 E:613 ||| NN
to  ||| S:613 E:616 ||| TO
this  ||| S:616 E:621 ||| DT
regimen  ||| S:621 E:629 ||| NN
( ||| S:629 E:630 ||| -LRB-
CHOP-R ||| S:630 E:636 ||| NNP
)  ||| S:636 E:638 ||| -RRB-
has  ||| S:638 E:642 ||| VBZ
helped  ||| S:642 E:649 ||| VBN
to  ||| S:649 E:652 ||| TO
improve  ||| S:652 E:660 ||| VB
patient  ||| S:660 E:668 ||| JJ
response  ||| S:668 E:677 ||| NN
to  ||| S:677 E:680 ||| TO
treatment ||| S:680 E:689 ||| NN
.  ||| S:689 E:691 ||| .
These  ||| S:691 E:697 ||| DT
treatments  ||| S:697 E:708 ||| NNS
often  ||| S:708 E:714 ||| RB
provide  ||| S:714 E:722 ||| VB
good  ||| S:722 E:727 ||| JJ
initial  ||| S:727 E:735 ||| JJ
responses  ||| S:735 E:745 ||| NNS
that  ||| S:745 E:750 ||| WDT
are  ||| S:750 E:754 ||| VBP
difficult  ||| S:754 E:764 ||| JJ
to  ||| S:764 E:767 ||| TO
sustain ||| S:767 E:774 ||| VB
.  ||| S:774 E:776 ||| .
Therefore ||| S:776 E:785 ||| RB
,  ||| S:785 E:787 ||| ,
a  ||| S:787 E:789 ||| DT
number  ||| S:789 E:796 ||| NN
of  ||| S:796 E:799 ||| IN
newer  ||| S:799 E:805 ||| JJR
agents  ||| S:805 E:812 ||| NNS
and  ||| S:812 E:816 ||| CC
combinations  ||| S:816 E:829 ||| NNS
have  ||| S:829 E:834 ||| VBP
been  ||| S:834 E:839 ||| VBN
investigated  ||| S:839 E:852 ||| VBN
to  ||| S:852 E:855 ||| TO
produce  ||| S:855 E:863 ||| VB
more  ||| S:863 E:868 ||| RBR
durable  ||| S:868 E:876 ||| JJ
benefit ||| S:876 E:883 ||| NN
.  ||| S:883 E:885 ||| .
Several  ||| S:885 E:893 ||| JJ
of  ||| S:893 E:896 ||| IN
these  ||| S:896 E:902 ||| DT
advances  ||| S:902 E:911 ||| NNS
were  ||| S:911 E:916 ||| VBD
reported  ||| S:916 E:925 ||| VBN
at  ||| S:925 E:928 ||| IN
the  ||| S:928 E:932 ||| DT
51st  ||| S:932 E:937 ||| NNP
American  ||| S:937 E:946 ||| NNP
Society  ||| S:946 E:954 ||| NNP
of  ||| S:954 E:957 ||| IN
Hematology  ||| S:957 E:968 ||| NNP
( ||| S:968 E:969 ||| -LRB-
ASH ||| S:969 E:972 ||| NNP
)  ||| S:972 E:974 ||| -RRB-
Annual  ||| S:974 E:981 ||| NNP
Meeting  ||| S:981 E:989 ||| NNP
and  ||| S:989 E:993 ||| CC
Exposition ||| S:993 E:1003 ||| NNP
,  ||| S:1003 E:1005 ||| ,
held  ||| S:1005 E:1010 ||| VBD
December  ||| S:1010 E:1019 ||| NNP
5-8 ||| S:1019 E:1022 ||| NNP
,  ||| S:1022 E:1024 ||| ,
2009  ||| S:1024 E:1029 ||| CD
in  ||| S:1029 E:1032 ||| IN
New  ||| S:1032 E:1036 ||| NNP
Orleans ||| S:1036 E:1043 ||| NNP
,  ||| S:1043 E:1045 ||| ,
Louisiana ||| S:1045 E:1054 ||| NNP
.  ||| S:1054 E:1056 ||| .
In  ||| S:1056 E:1059 ||| IN
this  ||| S:1059 E:1064 ||| DT
clinical  ||| S:1064 E:1073 ||| JJ
roundtable  ||| S:1073 E:1084 ||| JJ
monograph ||| S:1084 E:1093 ||| NN
,  ||| S:1093 E:1095 ||| ,
new  ||| S:1095 E:1099 ||| JJ
strategies  ||| S:1099 E:1110 ||| NNS
in  ||| S:1110 E:1113 ||| IN
the  ||| S:1113 E:1117 ||| DT
treatment  ||| S:1117 E:1127 ||| NN
of  ||| S:1127 E:1130 ||| IN
MCL  ||| S:1130 E:1134 ||| NNP
are  ||| S:1134 E:1138 ||| VBP
discussed ||| S:1138 E:1147 ||| VBN
.  ||| S:1147 E:1149 ||| .
Some  ||| S:1149 E:1154 ||| DT
of  ||| S:1154 E:1157 ||| IN
the  ||| S:1157 E:1161 ||| DT
drug  ||| S:1161 E:1166 ||| NN
classes  ||| S:1166 E:1174 ||| NNS
examined  ||| S:1174 E:1183 ||| VBD
here  ||| S:1183 E:1188 ||| RB
are  ||| S:1188 E:1192 ||| VBP
proteasome  ||| S:1192 E:1203 ||| JJ
inhibitors ||| S:1203 E:1213 ||| NN
,  ||| S:1213 E:1215 ||| ,
inhibitors  ||| S:1215 E:1226 ||| VBG
of  ||| S:1226 E:1229 ||| IN
the  ||| S:1229 E:1233 ||| DT
protein  ||| S:1233 E:1241 ||| NN
mammalian  ||| S:1241 E:1251 ||| NN
target  ||| S:1251 E:1258 ||| NN
of  ||| S:1258 E:1261 ||| IN
rapamycin  ||| S:1261 E:1271 ||| NNS
( ||| S:1271 E:1272 ||| -LRB-
mTOR ||| S:1272 E:1276 ||| NNP
) ||| S:1276 E:1277 ||| -RRB-
,  ||| S:1277 E:1279 ||| ,
the  ||| S:1279 E:1283 ||| DT
unique  ||| S:1283 E:1290 ||| JJ
alkylating  ||| S:1290 E:1301 ||| JJ
agent  ||| S:1301 E:1307 ||| NN
bendamustine ||| S:1307 E:1319 ||| NN
,  ||| S:1319 E:1321 ||| ,
and  ||| S:1321 E:1325 ||| CC
immunomodulatory  ||| S:1325 E:1342 ||| JJ
agents ||| S:1342 E:1348 ||| NNS
.  ||| S:1348 E:1350 ||| .
